Treatment for<unk>  includes glucocorticoids (such as prednisolone) and other immunosuppressive drugs (such as azathioprine and cyclophosphamide). In many cases, the disease can be put into a type of chemical remission through drug therapy, but the disease is chronic and lifelong. A systematic review conducted in 2007 indicated all patients should be treated with high-dose steroids, but in patients with a five-factor score of one or higher, cyclophosphamide pulse therapy should be commenced, with 12 pulses leading to fewer relapses than six. Remission can be maintained with a less toxic drug, such as azathioprine or methotrexate. On 12 December 2017, the FDA approved mepolizumab, the first drug therapy specifically indicated for the treatment of<unk> . Patients taking mepolizumab experienced a "significant improvement" in their symptoms. Mepolizumab is a monoclonal antibody that targets interleukin-5, a major factor in eosinophil survival. In addition to mepolizumab, a number of emerging targeted biotherapies—including the anti-IgE monoclonal antibody omalizumab, immunomodulation with Interferon-α, and B cell therapy with rituximab—may lead to increasingly personalized treatment regimens for future<unk>  patients. A review of<unk>  treatments conducted in 2020 proposes integrating targeted biotherapies into<unk>  management plans following failure of treatment with corticosteroids.
Eosinophilic granulomatosis with polyangiitis
Eosinophilic esophagitis
Granulomatosis with polyangiitis
Microscopic polyangiitis
Nephrogenic systemic fibrosis
Thromboangiitis obliterans
IgA vasculitis
Systemic vasculitis